CLS receives the first order from the National Institutes of Health Clinical Center in the US worth approximately 0.85 MSEK
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) has received an order for the company's TRANBERG system worth approximately 0.85 MSEK. The order was placed by the National Institutes of Health Clinical Center in the US, as part of the previously announced research collaboration between NIHCC and the company.
The National Institutes of Health Clinical Center (“NIH” or “NIH CC”) has placed its first order for CLS TRANBERG™ Thermal Therapy System. The order value amounts to approximately 0.85 MSEK, and is part of the research collaboration that was launched in April 2023, in which the company announced that the NIH will start using the system for MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.
"An important goal of the collaboration with NIH is for CLS to be able to demonstrate that image-guided focal laser ablation of cancerous tumors in the prostate, performed with our TRANBERG products, is a safe and effective treatment option with the absence of the typical side effects often associated with radiation and surgical treatment. We are honored and proud of the agreement with NIH CC and look forward to a productive and successful collaboration" says Dan J Mogren, CEO Clinical Laserthermia Systems AB.
Prostate cancer is one of the most common forms of cancer, and in the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
About the National Institutes of Health (NIH)
NIH, US medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: clinicallaser.se